BioFocus Announces Agreement with ChanTest
News Feb 07, 2013
BioFocus and ChanTest have announced an agreement which will enable BioFocus to offer ChanTest’s extensive cell line library (> 200 products) and Channel Panel™ profiling services.
This expands BioFocus’ offering in the fields of ion channel, GPCR and transporter targets for drug discovery.
“With access to ChanTest’s cell line collection and ion channel profiling, we have further augmented our suite of integrated drug discovery services, designed to deliver efficiency and success to our partners,” said Kate Hilyard, VP Biological Sciences, BioFocus.
Chris Mathes, Ph.D., M.B.A, Chief Commercial Officer, ChanTest, commented, “This collaboration with BioFocus fits well with ChanTest’s integrated CRO strategy, and we are delighted to partner with a company with such a strong reputation.”
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Epigenomic Analyses Could Lead to Novel Therapeutic Drug Targets for Many DiseasesNews
Researchers have decoded the epigenetic landscape for rheumatoid arthritis (RA), In unveiling RA’s epigenome scientists made a surprising discovery: an overlap between the causes of RA and Huntington’s disease, a fatal and incurable genetic brain disease.READ MORE
Combating Cancer by Targeting Sugar ReceptorsNews
Globally, cancer is the second leading cause of death, also because the efficiency of chemotherapeutics is inadequate due to poor delivery to the tumor. Prof. Olivia Merkel and her team develop targeted nanocarrier systems to increase the delivery rates of therapeutic formulations and their specific uptake into the target cells.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018